Posted by Michael Wonder on 02 May 2022
HAS clarifies the framework for use of Xevudy
29 April 2022 - After authorising early access to Xevudy (sotrovimab) as a curative treatment for COVID-19 on 6 January, HAS is now providing clarification on the framework for its use.
Indeed, the neutralising activity of this monoclonal antibody seems to be greatly reduced on the BA.2 sub-variant, which is the majority today.
Consequently, the HAS maintains the early access authorisation of this product only for patients affected by a strain other than the BA.2 sub-line of the Omicron variant.
